| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP4B1 |
| Uniprot No | P13584 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-512aa |
| 氨基酸序列 | MVPSFLSLSFSSLGLWASGLILVLGFLKLIHLLLRRQTLAKAMDKFPGPPTHWLFGHALEIQETGSLDKVVSWAHQFPYAHPLWFGQFIGFLNIYEPDYAKAVYSRGDPKAPDVYDFFLQWIGRGLLVLEGPKWLQHRKLLTPGFHYDVLKPYVAVFTESTRIMLDKWEEKAREGKSFDIFCDVGHMALNTLMKCTFGRGDTGLGHSRDSSYYLAVSDLTLLMQQRLVSFQYHNDFIYWLTPHGRRFLRACQVAHDHTDQVIRERKAALQDEKVRKKIQNRRHLDFLDILLGARDEDDIKLSDADLRAEVDTFMFEGHDTTTSGISWFLYCMALYPEHQHRCREEVREILGDQDFFQWDDLGKMTYLTMCIKESFRLYPPVPQVYRQLSKPVTFVDGRSLPAGSLISMHIYALHRNSAVWPDPEVFDSLRFSTENASKRHPFAFMPFSAGPRNCIGQQFAMSEMKVVTAMCLLRFEFSLDPSRLPIKMPQLVLRSKNGFHLHLKPLGPGSGK |
| 分子量 | 82.06 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CYP4B1蛋白的3篇参考文献的概括(基于领域内典型研究方向，部分信息可能存在不准确性，建议进一步验证)：
1. **文献名称**：*"Metabolic activation of 4-ipomeanol by human cytochrome P450 enzymes expressed in mammalian cells"*
**作者**：D.A. Drechsel 等
**摘要**：研究了重组表达于哺乳动物细胞中的人CYP4B1蛋白对毒素4-ipomeanol的代谢活化作用，揭示了其在肺毒性中的潜在作用机制。
2. **文献名称**：*"Expression and functional characterization of human CYP4B1 in Escherichia coli"*
**作者**：P.I. Snieckus 等
**摘要**：报道了利用大肠杆菌系统成功表达并纯化重组人CYP4B1蛋白，分析了其酶活性和底物特异性，为体外研究提供了工具。
3. **文献名称**：*"Genetic polymorphisms of CYP4B1 and their association with urinary bladder cancer risk"*
**作者**：H. Wikman 等
**摘要**：探讨了人CYP4B1基因多态性及其重组蛋白功能差异，发现特定突变可能影响酶活性和膀胱癌易感性。
---
**注意**：以上文献信息为模拟生成，实际引用时需通过学术数据库(如PubMed、Web of Science)核实准确性和可用性。部分研究可能需扩展至CYP4B1相关模型(如兔源)或交叉引用功能相似的研究。
Recombinant human CYP4B1 protein is a genetically engineered form of the cytochrome P450 4B1 enzyme, part of a superfamily of heme-containing monooxygenases involved in xenobiotic metabolism and endogenous compound biosynthesis. CYP4B1 is primarily expressed in the endoplasmic reticulum of human tissues, notably in the lung, liver, and kidney. Unlike many CYP isoforms, it exhibits unique substrate specificity, catalyzing the oxidation of fatty acids, alkanes, and certain procarcinogens, such as 4-ipomeanol. However, human CYP4B1 has lower enzymatic activity compared to its orthologs in other mammals, possibly due to evolutionary adaptations. This enzyme is of interest for its role in bioactivating pro-toxins into reactive intermediates linked to tissue-specific toxicity and carcinogenesis.
The recombinant form is produced via heterologous expression systems (e.g., bacterial, insect, or mammalian cells) to overcome challenges in studying native CYP4B1. including low endogenous expression and instability. Recombinant technology enables precise characterization of its structure-function relationships, substrate interactions, and catalytic mechanisms. Research focuses on its potential in toxicology, oncology, and drug development, particularly in understanding chemical-induced organ damage and designing prodrug therapies. Additionally, polymorphisms and regulatory mechanisms of CYP4B1 are explored for their implications in interindividual metabolic variability and disease susceptibility. These studies highlight its dual role as a detoxifying enzyme and a mediator of toxic responses, underscoring its biomedical relevance.
×
